First, we assess the nature of the tumoricidal interaction between nintedanib and silibinin and the underlying impact on STAT3 activity in a panel of human NSCLC cell lines [53,54,55,56,57,58]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.